Kherion Biotech

THE MOST VALUABLE BIOLOGICAL MATERIAL THE MOST ADVANCED TECHNOLOGY PLATFORM

NEW GENERATION BIOTECH AND HEALTH TECHNOLOGY
MULTI-DIRECTIONAL RESEARCH AND DEVELOPMENT ACTIVITIES

Kherion is developing a new category of regenerative medicine drugs and medicinal products. The products’ mechanism of action is based on the 100% biological nature of the original materials, which are already present within the body. The products re-create or replace the function of the original tissues and are used for various civilisation illnesses with zero side effects.

Kherion is a clinical trial biotech company and the global leader in the research, development and manufacturing of perinatal tissue-derived products for advanced treatment.

Kherion Biotech

Kherion is a new generation biotech and health technology company and has four main research and development areas including cellular and gene therapy, tissue engineering/biomaterial, functional foods and nutritional supplements and biomarker panels.

Kherion is following scientific developments, research and development activities aimed at developing cellular and gene therapy products for use in the treatment and prevention of diseases, and performs studies on developing stem cells, cellular products, tissue products, extracellular vesicles and immunotherapeutic products from different tissue sources.

Kherion is following the technological developments in the world and using current technologies such as three-dimensional bioprinters and new generation tissue engineering technologies. The products to be developed within the scope of biomaterial research and development activities with biocompatible, biodegradable properties will be products for bone and cartilage damage, tissue and organ damage, and wound and burn treatment.

Kherion is taking a holistic approach in the treatment and prevention of diseases, research and development studies are carried out to formulate functional foods and food supplements specific to many different diseases, especially neurological and neurodegenerative diseases (such as autism spectrum disorder, cerebral palsy, dementia).

Kherion believes that laboratory evaluations are important and a priority in the treatment and prevention of diseases, we closely follow the current scientific developments and, within the scope of research and development activities to develop biochemical, metabolic and genetic test panels. Kherion performs studies to develop many different test panels specific to diseases.

Our Science

Kherion's patented breakthrough biotechnology platform is a game changer in the field of tissue transplant functionality repurposing in many indications. Kherion holds key European patent ЕP3505196- AMNIPUR®, which is a versatile platform for the development and processing of amniotic membrane-based products. Another patented technology platform TECHSYMPHONY® is pending.

Kherion is a new generation biotechnology and health technology company and is a game changer in the four main areas including cellular and gene therapy, tissue engineering/biomaterial, functional foods and nutritional supplements and biomarker panels.

01 INITIATIVE

The impetus for development comes from collaborating physicians who lack a suitable solution for a particular medical indication.

02 POTENTIAL

Benefits and risks for new product development are evaluated internally within the company.

03 DEVELOPMENT

A development team works in the company's laboratories on the form and design of the new product. Throughout the development process, we are in close contact with specialists for the medical indication.

04 TRANSLATION

The last stage of development is the transfer of the product into practice: our products are manufactured according to GME.

Global Partnerships

Kherion is advancing international biotechnology partnerships, clinical research collaborations, and translational medicine hubs across key territories worldwide.

REGION

USA-Europe

USA Germany
REGION

Asia

South Korea Azerbaijan Uzbekistan

Product

Functional
Foods

Stage
Protein bar Prototype
Energy bar Prototype
Mineral-rich beverages Research-development

Tissue Engineering/
Biomaterials

Biomaterial + Stem cells Research-development
Biomaterial + Immune cells Research-development

Software
Technology

Digital Triage System Prototype

Other

Camouflage Cream Research-development

Publications

Year
Regeneration and repair of peripheral nerves with different biomaterials M Siemionow, M Bozkurt, F Zor Microsurgery 30 (7), 574-588 2010 A prospective analysis of free flap monitoring techniques: physical examination, external Doppler, implantable Doppler, and tissue oximetry RF Lohman, CJ Langevin, M Bozkurt, N Kundu, R Djohan Journal of reconstructive microsurgery 29 (01), 051-056 2013 Current concepts in the management of Marjolin's ulcers: outcomes from a standardized treatment protocol in 16 cases M Bozkurt, E Kapi, SV Kuvat, S Ozekinci Journal of burn care & research 31 (5), 776-780 2010 A new composite midface allotransplantation model with sensory and motor reinnervation F Zor, M Bozkurt, D Nair, M Siemionow Transplant International 23 (6), 649-656 2010 Dentition, bone loss, and the aging of the mandible CN Ozturk, C Ozturk, M Bozkurt, HS Uygur, FA Papay, JE Zins Aesthetic surgery journal 33 (7), 967-974 2013 New composite tissue allograft model of vascularized bone marrow transplant: the iliac osteomyocutaneous flap S Nasir, A Klimczak, E Sonmez, M Bozkurt, S Gibson, M Siemionow Transplant International 23 (1), 90-100 2010 Variables affecting postoperative tissue perfusion monitoring in free flap breast reconstruction CN Ozturk, C Ozturk, W Ledinh, M Bozkurt, G Schwarz, C O'Rourke, ... Microsurgery 35 (2), 123-128 2015 Evaluation of the effect of thymoquinone treatment on wound healing in a rat burn model CT Selçuk, M Durgun, R Tekin, lyas Yolbas, M Bozkurt, C Akçay, ... Journal of Burn Care & Research 34 (5), e274-e281 2013 Composite tissue allotransplantation MZ Siemionow, Y Kulahci, M Bozkurt Plastic and Reconstructive Surgery 124 (6), 327e-339e 2009 Large antigenic skin load in total abdominal wall transplants permits chimerism induction S Nasir, M Bozkurt, A Klimczak, M Siemionow Annals of Plastic Surgery 61 (5), 572-579 2008